Krystal Biotech to Report First Quarter 2024 Financial Results on May 6, 2024
26 April 2024 - 1:00PM
Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a
commercial-stage biotechnology company, today announced that it
will report its first quarter 2024 financial results
on Monday, May 6, 2024, prior to the open of U.S. markets.
The Company’s management will also host a conference call and
webcast at 8:30 am ET on Monday, May 6, 2024, to discuss
the financial results and provide a business update.
Investors and the general public can access the live webcast at:
https://www.webcaster4.com/Webcast/Page/3018/50407.
For those unable to listen to the live webcast, a replay will be
available for 30 days on the Investors section of the Company’s
website at www.krystalbio.com.
About Krystal Biotech, Inc.Krystal Biotech,
Inc. (NASDAQ: KRYS) is a commercial-stage biotechnology company
focused on the discovery, development and commercialization of
genetic medicines to treat diseases with high unmet medical needs.
VYJUVEK® is the Company’s first commercial product, the first-ever
redosable gene therapy, and the first medicine approved by the FDA
for the treatment of dystrophic epidermolysis bullosa. The Company
is rapidly advancing a robust preclinical and clinical pipeline of
investigational genetic medicines in respiratory, oncology,
dermatology, ophthalmology, and aesthetics. Krystal Biotech is
headquartered in Pittsburgh, Pennsylvania. For more information,
please visit http://www.krystalbio.com, and follow @KrystalBiotech
on LinkedIn and X (formerly Twitter).
CONTACTInvestors and Media:
Stéphane Paquette, PhDKrystal Biotechspaquette@krystalbio.com
Krystal Biotech (NASDAQ:KRYS)
Historical Stock Chart
Von Aug 2024 bis Sep 2024
Krystal Biotech (NASDAQ:KRYS)
Historical Stock Chart
Von Sep 2023 bis Sep 2024